nodes	percent_of_prediction	percent_of_DWPC	metapath
Nafarelin—Ophthalmoplegia—Lovastatin—atherosclerosis	0.0422	0.0531	CcSEcCtD
Nafarelin—IIIrd nerve paralysis—Lovastatin—atherosclerosis	0.0396	0.0498	CcSEcCtD
Nafarelin—Ophthalmoplegia—Simvastatin—atherosclerosis	0.0395	0.0497	CcSEcCtD
Nafarelin—IIIrd nerve paralysis—Simvastatin—atherosclerosis	0.037	0.0466	CcSEcCtD
Nafarelin—Ophthalmoplegia—Pravastatin—atherosclerosis	0.0357	0.0449	CcSEcCtD
Nafarelin—IIIrd nerve paralysis—Pravastatin—atherosclerosis	0.0335	0.0421	CcSEcCtD
Nafarelin—Mucous membrane disorder—Niacin—atherosclerosis	0.0262	0.033	CcSEcCtD
Nafarelin—High density lipoprotein decreased—Niacin—atherosclerosis	0.0262	0.033	CcSEcCtD
Nafarelin—Loss of libido—Lovastatin—atherosclerosis	0.0133	0.0167	CcSEcCtD
Nafarelin—Loss of libido—Simvastatin—atherosclerosis	0.0124	0.0156	CcSEcCtD
Nafarelin—Ascites—Niacin—atherosclerosis	0.0116	0.0146	CcSEcCtD
Nafarelin—Loss of libido—Pravastatin—atherosclerosis	0.0112	0.0141	CcSEcCtD
Nafarelin—Libido increased—Niacin—atherosclerosis	0.00865	0.0109	CcSEcCtD
Nafarelin—Interstitial lung disease—Ezetimibe—atherosclerosis	0.00849	0.0107	CcSEcCtD
Nafarelin—Myasthenia—Niacin—atherosclerosis	0.00837	0.0105	CcSEcCtD
Nafarelin—GNRHR—Peptide GPCRs—CX3CR1—atherosclerosis	0.00834	0.0406	CbGpPWpGaD
Nafarelin—Interstitial lung disease—Simvastatin—atherosclerosis	0.00809	0.0102	CcSEcCtD
Nafarelin—Interstitial lung disease—Pravastatin—atherosclerosis	0.00732	0.00921	CcSEcCtD
Nafarelin—Gynaecomastia—Rosuvastatin—atherosclerosis	0.00647	0.00814	CcSEcCtD
Nafarelin—GNRHR—G alpha (q) signalling events—HRH1—atherosclerosis	0.00643	0.0313	CbGpPWpGaD
Nafarelin—Breast pain—Niacin—atherosclerosis	0.00603	0.00759	CcSEcCtD
Nafarelin—GNRHR—Peptide GPCRs—CCR2—atherosclerosis	0.00603	0.0294	CbGpPWpGaD
Nafarelin—GNRHR—Peptide GPCRs—EDNRA—atherosclerosis	0.00603	0.0294	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—HRH1—atherosclerosis	0.00575	0.028	CbGpPWpGaD
Nafarelin—Gynaecomastia—Lovastatin—atherosclerosis	0.00548	0.00689	CcSEcCtD
Nafarelin—Gynaecomastia—Simvastatin—atherosclerosis	0.00513	0.00645	CcSEcCtD
Nafarelin—GNRHR—Peptide GPCRs—AGTR1—atherosclerosis	0.00513	0.025	CbGpPWpGaD
Nafarelin—GNRHR—GPCRs, Other—EDNRA—atherosclerosis	0.00511	0.0249	CbGpPWpGaD
Nafarelin—Hepatic function abnormal—Lovastatin—atherosclerosis	0.00509	0.0064	CcSEcCtD
Nafarelin—Rash maculo-papular—Niacin—atherosclerosis	0.00478	0.00602	CcSEcCtD
Nafarelin—Hepatic function abnormal—Simvastatin—atherosclerosis	0.00476	0.00599	CcSEcCtD
Nafarelin—Hot flush—Ezetimibe—atherosclerosis	0.00466	0.00586	CcSEcCtD
Nafarelin—Gynaecomastia—Pravastatin—atherosclerosis	0.00463	0.00583	CcSEcCtD
Nafarelin—Muscular weakness—Rosuvastatin—atherosclerosis	0.00463	0.00582	CcSEcCtD
Nafarelin—Menopausal symptoms—Ezetimibe—atherosclerosis	0.00462	0.00581	CcSEcCtD
Nafarelin—Hepatic function abnormal—Niacin—atherosclerosis	0.00437	0.0055	CcSEcCtD
Nafarelin—Hepatic function abnormal—Pravastatin—atherosclerosis	0.0043	0.00541	CcSEcCtD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—HRH1—atherosclerosis	0.00426	0.0208	CbGpPWpGaD
Nafarelin—GNRHR—G alpha (q) signalling events—UTS2—atherosclerosis	0.00414	0.0202	CbGpPWpGaD
Nafarelin—Depression—Rosuvastatin—atherosclerosis	0.00403	0.00507	CcSEcCtD
Nafarelin—Hot flush—Pravastatin—atherosclerosis	0.00402	0.00506	CcSEcCtD
Nafarelin—Menopausal symptoms—Pravastatin—atherosclerosis	0.00398	0.00501	CcSEcCtD
Nafarelin—GNRHR—G alpha (q) signalling events—CASR—atherosclerosis	0.00397	0.0194	CbGpPWpGaD
Nafarelin—Gastritis—Ezetimibe—atherosclerosis	0.00386	0.00486	CcSEcCtD
Nafarelin—Muscular weakness—Ezetimibe—atherosclerosis	0.00385	0.00484	CcSEcCtD
Nafarelin—Sinusitis—Rosuvastatin—atherosclerosis	0.00379	0.00477	CcSEcCtD
Nafarelin—Disturbance in sexual arousal—Niacin—atherosclerosis	0.00379	0.00477	CcSEcCtD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—UTS2—atherosclerosis	0.0037	0.0181	CbGpPWpGaD
Nafarelin—Affect lability—Pravastatin—atherosclerosis	0.0037	0.00466	CcSEcCtD
Nafarelin—Gastritis—Simvastatin—atherosclerosis	0.00368	0.00463	CcSEcCtD
Nafarelin—Muscular weakness—Simvastatin—atherosclerosis	0.00367	0.00461	CcSEcCtD
Nafarelin—Rhinitis—Rosuvastatin—atherosclerosis	0.00364	0.00458	CcSEcCtD
Nafarelin—Mood swings—Pravastatin—atherosclerosis	0.00356	0.00448	CcSEcCtD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—CASR—atherosclerosis	0.00355	0.0173	CbGpPWpGaD
Nafarelin—Dry skin—Niacin—atherosclerosis	0.0035	0.0044	CcSEcCtD
Nafarelin—Dry skin—Pravastatin—atherosclerosis	0.00345	0.00434	CcSEcCtD
Nafarelin—Muscular weakness—Niacin—atherosclerosis	0.00337	0.00424	CcSEcCtD
Nafarelin—Abdominal distension—Niacin—atherosclerosis	0.00332	0.00418	CcSEcCtD
Nafarelin—Muscular weakness—Pravastatin—atherosclerosis	0.00332	0.00417	CcSEcCtD
Nafarelin—Abdominal distension—Pravastatin—atherosclerosis	0.00327	0.00412	CcSEcCtD
Nafarelin—GNRHR—GPCR ligand binding—HRH1—atherosclerosis	0.00324	0.0158	CbGpPWpGaD
Nafarelin—Sinusitis—Lovastatin—atherosclerosis	0.00321	0.00404	CcSEcCtD
Nafarelin—Depression—Simvastatin—atherosclerosis	0.0032	0.00402	CcSEcCtD
Nafarelin—Mental disorder—Rosuvastatin—atherosclerosis	0.00318	0.004	CcSEcCtD
Nafarelin—Sweating increased—Pravastatin—atherosclerosis	0.00317	0.00398	CcSEcCtD
Nafarelin—Sinusitis—Ezetimibe—atherosclerosis	0.00315	0.00397	CcSEcCtD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CCL4—atherosclerosis	0.00308	0.015	CbGpPWpGaD
Nafarelin—Dysuria—Pravastatin—atherosclerosis	0.00304	0.00382	CcSEcCtD
Nafarelin—Sinusitis—Simvastatin—atherosclerosis	0.00301	0.00378	CcSEcCtD
Nafarelin—Weight increased—Pravastatin—atherosclerosis	0.00296	0.00372	CcSEcCtD
Nafarelin—Weight decreased—Pravastatin—atherosclerosis	0.00294	0.0037	CcSEcCtD
Nafarelin—Depression—Pravastatin—atherosclerosis	0.00289	0.00363	CcSEcCtD
Nafarelin—GNRHR—G alpha (q) signalling events—EDNRA—atherosclerosis	0.00287	0.014	CbGpPWpGaD
Nafarelin—Acute coronary syndrome—Pravastatin—atherosclerosis	0.00286	0.00359	CcSEcCtD
Nafarelin—Myocardial infarction—Pravastatin—atherosclerosis	0.00284	0.00357	CcSEcCtD
Nafarelin—GNRHR—G alpha (q) signalling events—GHRL—atherosclerosis	0.0028	0.0136	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—UTS2—atherosclerosis	0.00274	0.0134	CbGpPWpGaD
Nafarelin—Sinusitis—Pravastatin—atherosclerosis	0.00272	0.00342	CcSEcCtD
Nafarelin—Alopecia—Lovastatin—atherosclerosis	0.00272	0.00342	CcSEcCtD
Nafarelin—Myalgia—Rosuvastatin—atherosclerosis	0.00269	0.00338	CcSEcCtD
Nafarelin—Arthralgia—Rosuvastatin—atherosclerosis	0.00269	0.00338	CcSEcCtD
Nafarelin—Alopecia—Ezetimibe—atherosclerosis	0.00267	0.00335	CcSEcCtD
Nafarelin—Rhinitis—Niacin—atherosclerosis	0.00265	0.00333	CcSEcCtD
Nafarelin—Mental disorder—Ezetimibe—atherosclerosis	0.00264	0.00333	CcSEcCtD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CX3CR1—atherosclerosis	0.00263	0.0128	CbGpPWpGaD
Nafarelin—Malnutrition—Ezetimibe—atherosclerosis	0.00263	0.0033	CcSEcCtD
Nafarelin—Dysgeusia—Lovastatin—atherosclerosis	0.00262	0.0033	CcSEcCtD
Nafarelin—Rhinitis—Pravastatin—atherosclerosis	0.00261	0.00328	CcSEcCtD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CX3CL1—atherosclerosis	0.00258	0.0126	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—EDNRA—atherosclerosis	0.00257	0.0125	CbGpPWpGaD
Nafarelin—Alopecia—Simvastatin—atherosclerosis	0.00254	0.0032	CcSEcCtD
Nafarelin—Mental disorder—Simvastatin—atherosclerosis	0.00252	0.00317	CcSEcCtD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—GHRL—atherosclerosis	0.0025	0.0122	CbGpPWpGaD
Nafarelin—GNRHR—G alpha (q) signalling events—KNG1—atherosclerosis	0.00246	0.012	CbGpPWpGaD
Nafarelin—Dysgeusia—Simvastatin—atherosclerosis	0.00245	0.00309	CcSEcCtD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CNR2—atherosclerosis	0.00245	0.0119	CbGpPWpGaD
Nafarelin—GNRHR—G alpha (q) signalling events—AGTR1—atherosclerosis	0.00244	0.0119	CbGpPWpGaD
Nafarelin—Vertigo—Lovastatin—atherosclerosis	0.00241	0.00303	CcSEcCtD
Nafarelin—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.00235	0.00296	CcSEcCtD
Nafarelin—GNRHR—GPCR ligand binding—CCL4—atherosclerosis	0.00234	0.0114	CbGpPWpGaD
Nafarelin—Alopecia—Niacin—atherosclerosis	0.00233	0.00294	CcSEcCtD
Nafarelin—Insomnia—Rosuvastatin—atherosclerosis	0.00233	0.00293	CcSEcCtD
Nafarelin—Palpitations—Ezetimibe—atherosclerosis	0.00232	0.00292	CcSEcCtD
Nafarelin—Paraesthesia—Rosuvastatin—atherosclerosis	0.00232	0.00291	CcSEcCtD
Nafarelin—Malnutrition—Niacin—atherosclerosis	0.0023	0.00289	CcSEcCtD
Nafarelin—Alopecia—Pravastatin—atherosclerosis	0.0023	0.00289	CcSEcCtD
Nafarelin—Chest pain—Lovastatin—atherosclerosis	0.00228	0.00287	CcSEcCtD
Nafarelin—Arthralgia—Lovastatin—atherosclerosis	0.00228	0.00287	CcSEcCtD
Nafarelin—Myalgia—Lovastatin—atherosclerosis	0.00228	0.00287	CcSEcCtD
Nafarelin—Tension—Niacin—atherosclerosis	0.00226	0.00284	CcSEcCtD
Nafarelin—Vertigo—Simvastatin—atherosclerosis	0.00225	0.00283	CcSEcCtD
Nafarelin—Arthralgia—Ezetimibe—atherosclerosis	0.00224	0.00281	CcSEcCtD
Nafarelin—Myalgia—Ezetimibe—atherosclerosis	0.00224	0.00281	CcSEcCtD
Nafarelin—Chest pain—Ezetimibe—atherosclerosis	0.00224	0.00281	CcSEcCtD
Nafarelin—Nervousness—Niacin—atherosclerosis	0.00223	0.00281	CcSEcCtD
Nafarelin—Tension—Pravastatin—atherosclerosis	0.00222	0.0028	CcSEcCtD
Nafarelin—Dysgeusia—Pravastatin—atherosclerosis	0.00222	0.00279	CcSEcCtD
Nafarelin—Constipation—Rosuvastatin—atherosclerosis	0.00221	0.00277	CcSEcCtD
Nafarelin—Nervousness—Pravastatin—atherosclerosis	0.0022	0.00277	CcSEcCtD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—KNG1—atherosclerosis	0.0022	0.0107	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—AGTR1—atherosclerosis	0.00218	0.0106	CbGpPWpGaD
Nafarelin—Myalgia—Simvastatin—atherosclerosis	0.00213	0.00268	CcSEcCtD
Nafarelin—Arthralgia—Simvastatin—atherosclerosis	0.00213	0.00268	CcSEcCtD
Nafarelin—Chest pain—Simvastatin—atherosclerosis	0.00213	0.00268	CcSEcCtD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CCL3—atherosclerosis	0.0021	0.0102	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—UTS2—atherosclerosis	0.00209	0.0102	CbGpPWpGaD
Nafarelin—Anorexia—Lovastatin—atherosclerosis	0.00208	0.00262	CcSEcCtD
Nafarelin—GNRHR—G alpha (q) signalling events—EDN1—atherosclerosis	0.00207	0.0101	CbGpPWpGaD
Nafarelin—Vertigo—Niacin—atherosclerosis	0.00207	0.0026	CcSEcCtD
Nafarelin—Urticaria—Rosuvastatin—atherosclerosis	0.00205	0.00258	CcSEcCtD
Nafarelin—Oedema—Simvastatin—atherosclerosis	0.00204	0.00257	CcSEcCtD
Nafarelin—Vertigo—Pravastatin—atherosclerosis	0.00203	0.00256	CcSEcCtD
Nafarelin—Palpitations—Niacin—atherosclerosis	0.00203	0.00256	CcSEcCtD
Nafarelin—GNRHR—GPCR ligand binding—CX3CR1—atherosclerosis	0.002	0.00976	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—CASR—atherosclerosis	0.002	0.00976	CbGpPWpGaD
Nafarelin—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.00199	0.0025	CcSEcCtD
Nafarelin—Insomnia—Lovastatin—atherosclerosis	0.00198	0.00249	CcSEcCtD
Nafarelin—GNRHR—GPCR ligand binding—CX3CL1—atherosclerosis	0.00196	0.00957	CbGpPWpGaD
Nafarelin—Paraesthesia—Lovastatin—atherosclerosis	0.00196	0.00247	CcSEcCtD
Nafarelin—Arthralgia—Niacin—atherosclerosis	0.00196	0.00246	CcSEcCtD
Nafarelin—Myalgia—Niacin—atherosclerosis	0.00196	0.00246	CcSEcCtD
Nafarelin—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.00195	0.00246	CcSEcCtD
Nafarelin—Anorexia—Simvastatin—atherosclerosis	0.00195	0.00245	CcSEcCtD
Nafarelin—Dyspnoea—Lovastatin—atherosclerosis	0.00195	0.00245	CcSEcCtD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—MMP3—atherosclerosis	0.00195	0.00949	CbGpPWpGaD
Nafarelin—Insomnia—Ezetimibe—atherosclerosis	0.00194	0.00244	CcSEcCtD
Nafarelin—Chest pain—Pravastatin—atherosclerosis	0.00193	0.00243	CcSEcCtD
Nafarelin—Myalgia—Pravastatin—atherosclerosis	0.00193	0.00243	CcSEcCtD
Nafarelin—Arthralgia—Pravastatin—atherosclerosis	0.00193	0.00243	CcSEcCtD
Nafarelin—Paraesthesia—Ezetimibe—atherosclerosis	0.00192	0.00242	CcSEcCtD
Nafarelin—Dyspnoea—Ezetimibe—atherosclerosis	0.00191	0.0024	CcSEcCtD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—EDNRA—atherosclerosis	0.0019	0.00927	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CCR2—atherosclerosis	0.0019	0.00927	CbGpPWpGaD
Nafarelin—Decreased appetite—Lovastatin—atherosclerosis	0.0019	0.00239	CcSEcCtD
Nafarelin—Oedema—Niacin—atherosclerosis	0.00188	0.00236	CcSEcCtD
Nafarelin—Constipation—Lovastatin—atherosclerosis	0.00187	0.00235	CcSEcCtD
Nafarelin—Decreased appetite—Ezetimibe—atherosclerosis	0.00186	0.00234	CcSEcCtD
Nafarelin—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.00186	0.00234	CcSEcCtD
Nafarelin—GNRHR—GPCR ligand binding—CNR2—atherosclerosis	0.00186	0.00908	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—GHRL—atherosclerosis	0.00185	0.00903	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—atherosclerosis	0.00185	0.00902	CbGpPWpGaD
Nafarelin—Asthenia—Rosuvastatin—atherosclerosis	0.00185	0.00233	CcSEcCtD
Nafarelin—Insomnia—Simvastatin—atherosclerosis	0.00185	0.00233	CcSEcCtD
Nafarelin—Oedema—Pravastatin—atherosclerosis	0.00185	0.00232	CcSEcCtD
Nafarelin—Shock—Niacin—atherosclerosis	0.00185	0.00232	CcSEcCtD
Nafarelin—Paraesthesia—Simvastatin—atherosclerosis	0.00184	0.00231	CcSEcCtD
Nafarelin—Constipation—Ezetimibe—atherosclerosis	0.00183	0.00231	CcSEcCtD
Nafarelin—GNRHR—GPCR downstream signaling—HRH1—atherosclerosis	0.00183	0.00893	CbGpPWpGaD
Nafarelin—Pruritus—Rosuvastatin—atherosclerosis	0.00182	0.0023	CcSEcCtD
Nafarelin—Dyspnoea—Simvastatin—atherosclerosis	0.00182	0.00229	CcSEcCtD
Nafarelin—Hyperhidrosis—Niacin—atherosclerosis	0.00181	0.00228	CcSEcCtD
Nafarelin—Anorexia—Niacin—atherosclerosis	0.00179	0.00225	CcSEcCtD
Nafarelin—Hyperhidrosis—Pravastatin—atherosclerosis	0.00179	0.00225	CcSEcCtD
Nafarelin—Decreased appetite—Simvastatin—atherosclerosis	0.00178	0.00224	CcSEcCtD
Nafarelin—Diarrhoea—Rosuvastatin—atherosclerosis	0.00176	0.00222	CcSEcCtD
Nafarelin—Anorexia—Pravastatin—atherosclerosis	0.00176	0.00222	CcSEcCtD
Nafarelin—Constipation—Simvastatin—atherosclerosis	0.00175	0.0022	CcSEcCtD
Nafarelin—Urticaria—Lovastatin—atherosclerosis	0.00174	0.00218	CcSEcCtD
Nafarelin—GNRHR—G alpha (q) signalling events—AGT—atherosclerosis	0.00172	0.00837	CbGpPWpGaD
Nafarelin—Musculoskeletal discomfort—Niacin—atherosclerosis	0.00171	0.00215	CcSEcCtD
Nafarelin—Dizziness—Rosuvastatin—atherosclerosis	0.00171	0.00215	CcSEcCtD
Nafarelin—Urticaria—Ezetimibe—atherosclerosis	0.0017	0.00214	CcSEcCtD
Nafarelin—Insomnia—Niacin—atherosclerosis	0.0017	0.00214	CcSEcCtD
Nafarelin—Paraesthesia—Niacin—atherosclerosis	0.00169	0.00212	CcSEcCtD
Nafarelin—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.00168	0.00212	CcSEcCtD
Nafarelin—Dyspnoea—Niacin—atherosclerosis	0.00167	0.00211	CcSEcCtD
Nafarelin—Insomnia—Pravastatin—atherosclerosis	0.00167	0.0021	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—HRH1—atherosclerosis	0.00166	0.00811	CbGpPWpGaD
Nafarelin—Paraesthesia—Pravastatin—atherosclerosis	0.00166	0.00209	CcSEcCtD
Nafarelin—Dyspnoea—Pravastatin—atherosclerosis	0.00165	0.00207	CcSEcCtD
Nafarelin—Decreased appetite—Niacin—atherosclerosis	0.00163	0.00205	CcSEcCtD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—KNG1—atherosclerosis	0.00163	0.00793	CbGpPWpGaD
Nafarelin—Rash—Rosuvastatin—atherosclerosis	0.00163	0.00205	CcSEcCtD
Nafarelin—Dermatitis—Rosuvastatin—atherosclerosis	0.00162	0.00204	CcSEcCtD
Nafarelin—Urticaria—Simvastatin—atherosclerosis	0.00162	0.00204	CcSEcCtD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—AGTR1—atherosclerosis	0.00162	0.00788	CbGpPWpGaD
Nafarelin—Headache—Rosuvastatin—atherosclerosis	0.00162	0.00203	CcSEcCtD
Nafarelin—Decreased appetite—Pravastatin—atherosclerosis	0.00161	0.00202	CcSEcCtD
Nafarelin—GNRHR—GPCR ligand binding—CCL3—atherosclerosis	0.0016	0.0078	CbGpPWpGaD
Nafarelin—GNRHR—G alpha (q) signalling events—F2—atherosclerosis	0.00159	0.00774	CbGpPWpGaD
Nafarelin—Constipation—Pravastatin—atherosclerosis	0.00158	0.00199	CcSEcCtD
Nafarelin—Asthenia—Lovastatin—atherosclerosis	0.00157	0.00197	CcSEcCtD
Nafarelin—Pruritus—Lovastatin—atherosclerosis	0.00155	0.00195	CcSEcCtD
Nafarelin—Asthenia—Ezetimibe—atherosclerosis	0.00154	0.00193	CcSEcCtD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—atherosclerosis	0.00154	0.00749	CbGpPWpGaD
Nafarelin—Nausea—Rosuvastatin—atherosclerosis	0.00153	0.00193	CcSEcCtD
Nafarelin—Pruritus—Ezetimibe—atherosclerosis	0.00152	0.00191	CcSEcCtD
Nafarelin—Diarrhoea—Lovastatin—atherosclerosis	0.0015	0.00188	CcSEcCtD
Nafarelin—Urticaria—Niacin—atherosclerosis	0.00149	0.00188	CcSEcCtD
Nafarelin—Urticaria—Pravastatin—atherosclerosis	0.00147	0.00185	CcSEcCtD
Nafarelin—Asthenia—Simvastatin—atherosclerosis	0.00147	0.00185	CcSEcCtD
Nafarelin—Diarrhoea—Ezetimibe—atherosclerosis	0.00147	0.00185	CcSEcCtD
Nafarelin—GNRHR—GPCR ligand binding—EDNRA—atherosclerosis	0.00145	0.00706	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—CCR2—atherosclerosis	0.00145	0.00706	CbGpPWpGaD
Nafarelin—Pruritus—Simvastatin—atherosclerosis	0.00145	0.00182	CcSEcCtD
Nafarelin—Dizziness—Lovastatin—atherosclerosis	0.00145	0.00182	CcSEcCtD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—F2—atherosclerosis	0.00142	0.00692	CbGpPWpGaD
Nafarelin—Dizziness—Ezetimibe—atherosclerosis	0.00142	0.00178	CcSEcCtD
Nafarelin—GNRHR—GPCR ligand binding—GHRL—atherosclerosis	0.00141	0.00688	CbGpPWpGaD
Nafarelin—Diarrhoea—Simvastatin—atherosclerosis	0.0014	0.00176	CcSEcCtD
Nafarelin—Vomiting—Lovastatin—atherosclerosis	0.00139	0.00175	CcSEcCtD
Nafarelin—Rash—Lovastatin—atherosclerosis	0.00138	0.00173	CcSEcCtD
Nafarelin—Dermatitis—Lovastatin—atherosclerosis	0.00138	0.00173	CcSEcCtD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—EDN1—atherosclerosis	0.00137	0.00668	CbGpPWpGaD
Nafarelin—Headache—Lovastatin—atherosclerosis	0.00137	0.00172	CcSEcCtD
Nafarelin—Vomiting—Ezetimibe—atherosclerosis	0.00136	0.00171	CcSEcCtD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CCL5—atherosclerosis	0.00136	0.00663	CbGpPWpGaD
Nafarelin—Dizziness—Simvastatin—atherosclerosis	0.00135	0.0017	CcSEcCtD
Nafarelin—Rash—Ezetimibe—atherosclerosis	0.00135	0.0017	CcSEcCtD
Nafarelin—Dermatitis—Ezetimibe—atherosclerosis	0.00135	0.0017	CcSEcCtD
Nafarelin—Asthenia—Niacin—atherosclerosis	0.00135	0.00169	CcSEcCtD
Nafarelin—Headache—Ezetimibe—atherosclerosis	0.00134	0.00169	CcSEcCtD
Nafarelin—Pruritus—Niacin—atherosclerosis	0.00133	0.00167	CcSEcCtD
Nafarelin—Asthenia—Pravastatin—atherosclerosis	0.00133	0.00167	CcSEcCtD
Nafarelin—Pruritus—Pravastatin—atherosclerosis	0.00131	0.00164	CcSEcCtD
Nafarelin—Vomiting—Simvastatin—atherosclerosis	0.0013	0.00164	CcSEcCtD
Nafarelin—Nausea—Lovastatin—atherosclerosis	0.0013	0.00163	CcSEcCtD
Nafarelin—Rash—Simvastatin—atherosclerosis	0.00129	0.00162	CcSEcCtD
Nafarelin—Dermatitis—Simvastatin—atherosclerosis	0.00129	0.00162	CcSEcCtD
Nafarelin—Diarrhoea—Niacin—atherosclerosis	0.00128	0.00162	CcSEcCtD
Nafarelin—Headache—Simvastatin—atherosclerosis	0.00128	0.00161	CcSEcCtD
Nafarelin—Nausea—Ezetimibe—atherosclerosis	0.00127	0.0016	CcSEcCtD
Nafarelin—Diarrhoea—Pravastatin—atherosclerosis	0.00126	0.00159	CcSEcCtD
Nafarelin—Dizziness—Niacin—atherosclerosis	0.00124	0.00156	CcSEcCtD
Nafarelin—GNRHR—GPCR ligand binding—KNG1—atherosclerosis	0.00124	0.00604	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—AGTR1—atherosclerosis	0.00123	0.006	CbGpPWpGaD
Nafarelin—Dizziness—Pravastatin—atherosclerosis	0.00122	0.00154	CcSEcCtD
Nafarelin—Nausea—Simvastatin—atherosclerosis	0.00121	0.00153	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—CCL4—atherosclerosis	0.0012	0.00586	CbGpPWpGaD
Nafarelin—Vomiting—Niacin—atherosclerosis	0.00119	0.0015	CcSEcCtD
Nafarelin—Rash—Niacin—atherosclerosis	0.00118	0.00149	CcSEcCtD
Nafarelin—Dermatitis—Niacin—atherosclerosis	0.00118	0.00149	CcSEcCtD
Nafarelin—GNRHR—GPCR downstream signaling—UTS2—atherosclerosis	0.00118	0.00575	CbGpPWpGaD
Nafarelin—Headache—Niacin—atherosclerosis	0.00118	0.00148	CcSEcCtD
Nafarelin—Vomiting—Pravastatin—atherosclerosis	0.00117	0.00148	CcSEcCtD
Nafarelin—Rash—Pravastatin—atherosclerosis	0.00117	0.00147	CcSEcCtD
Nafarelin—Dermatitis—Pravastatin—atherosclerosis	0.00116	0.00146	CcSEcCtD
Nafarelin—Headache—Pravastatin—atherosclerosis	0.00116	0.00146	CcSEcCtD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—AGT—atherosclerosis	0.00114	0.00555	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—CASR—atherosclerosis	0.00113	0.00552	CbGpPWpGaD
Nafarelin—Nausea—Niacin—atherosclerosis	0.00111	0.0014	CcSEcCtD
Nafarelin—Nausea—Pravastatin—atherosclerosis	0.0011	0.00138	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—UTS2—atherosclerosis	0.00107	0.00523	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—CNR2—atherosclerosis	0.00105	0.00513	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—F2—atherosclerosis	0.00105	0.00512	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—EDN1—atherosclerosis	0.00104	0.00509	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—CCL5—atherosclerosis	0.00104	0.00505	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—CASR—atherosclerosis	0.00103	0.00501	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—CX3CR1—atherosclerosis	0.00103	0.00501	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—CX3CL1—atherosclerosis	0.00101	0.00491	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—HRH1—atherosclerosis	0.000983	0.00479	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—CNR2—atherosclerosis	0.000956	0.00466	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CCL2—atherosclerosis	0.000937	0.00457	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—AGT—atherosclerosis	0.000866	0.00422	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—CCL3—atherosclerosis	0.000822	0.00401	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—CCR2—atherosclerosis	0.000818	0.00399	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—EDNRA—atherosclerosis	0.000818	0.00399	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—F2—atherosclerosis	0.000801	0.0039	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—GHRL—atherosclerosis	0.000797	0.00389	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—APOA4—atherosclerosis	0.000771	0.00376	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—atherosclerosis	0.000769	0.00375	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—EDNRA—atherosclerosis	0.000743	0.00362	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—CCR2—atherosclerosis	0.000743	0.00362	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CXCL8—atherosclerosis	0.000741	0.00361	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—GHRL—atherosclerosis	0.000724	0.00353	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—CCL2—atherosclerosis	0.000714	0.00348	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CCL4—atherosclerosis	0.000711	0.00346	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—KNG1—atherosclerosis	0.0007	0.00341	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—AGTR1—atherosclerosis	0.000696	0.00339	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—APOA2—atherosclerosis	0.000664	0.00324	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—KNG1—atherosclerosis	0.000636	0.0031	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—UTS2—atherosclerosis	0.000633	0.00309	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—AGTR1—atherosclerosis	0.000632	0.00308	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CX3CR1—atherosclerosis	0.000607	0.00296	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CASR—atherosclerosis	0.000607	0.00296	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CX3CL1—atherosclerosis	0.000595	0.0029	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—EDN1—atherosclerosis	0.00059	0.00288	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—CCL5—atherosclerosis	0.000585	0.00285	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CNR2—atherosclerosis	0.000564	0.00275	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—CXCL8—atherosclerosis	0.000564	0.00275	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—MMP3—atherosclerosis	0.000563	0.00275	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—atherosclerosis	0.000562	0.00274	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—PRKCG—atherosclerosis	0.000556	0.00271	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—EDN1—atherosclerosis	0.000536	0.00261	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—CCL5—atherosclerosis	0.000532	0.00259	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—PRKCG—atherosclerosis	0.000505	0.00246	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—VWF—atherosclerosis	0.000503	0.00245	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—APOC3—atherosclerosis	0.0005	0.00244	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—LDLR—atherosclerosis	0.000497	0.00242	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—AGT—atherosclerosis	0.00049	0.00239	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CCL3—atherosclerosis	0.000485	0.00237	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—NCF1—atherosclerosis	0.000465	0.00227	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—F2—atherosclerosis	0.000452	0.00221	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—AGT—atherosclerosis	0.000445	0.00217	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—EDNRA—atherosclerosis	0.000439	0.00214	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CCR2—atherosclerosis	0.000439	0.00214	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CYBA—atherosclerosis	0.000437	0.00213	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—PIK3CG—atherosclerosis	0.000433	0.00211	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—PLAT—atherosclerosis	0.000428	0.00209	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—GHRL—atherosclerosis	0.000428	0.00209	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—PARP1—atherosclerosis	0.000428	0.00209	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—F2—atherosclerosis	0.000411	0.002	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—PIK3CG—atherosclerosis	0.000393	0.00192	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—KNG1—atherosclerosis	0.000375	0.00183	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—AGTR1—atherosclerosis	0.000373	0.00182	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—CCL2—atherosclerosis	0.000366	0.00178	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—PLG—atherosclerosis	0.000364	0.00177	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—SOCS3—atherosclerosis	0.000344	0.00168	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—MMP3—atherosclerosis	0.000333	0.00162	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—IGF2—atherosclerosis	0.000331	0.00161	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—APOB—atherosclerosis	0.000322	0.00157	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—CXCL8—atherosclerosis	0.000319	0.00155	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—EDN1—atherosclerosis	0.000316	0.00154	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CCL5—atherosclerosis	0.000314	0.00153	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—LPL—atherosclerosis	0.000307	0.0015	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—PRKCG—atherosclerosis	0.000299	0.00146	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—SPP1—atherosclerosis	0.000291	0.00142	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—CXCL8—atherosclerosis	0.000289	0.00141	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—PDGFB—atherosclerosis	0.000269	0.00131	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—AGT—atherosclerosis	0.000263	0.00128	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—LEP—atherosclerosis	0.000257	0.00125	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—APOE—atherosclerosis	0.000257	0.00125	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CAV1—atherosclerosis	0.000255	0.00124	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—APOA1—atherosclerosis	0.000254	0.00124	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—ESR1—atherosclerosis	0.000246	0.0012	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—F2—atherosclerosis	0.000243	0.00118	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—PIK3CG—atherosclerosis	0.000232	0.00113	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—MAPK3—atherosclerosis	0.000222	0.00108	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—INS—atherosclerosis	0.00022	0.00107	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CCL2—atherosclerosis	0.000216	0.00105	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—IGF1—atherosclerosis	0.000213	0.00104	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—SERPINE1—atherosclerosis	0.000202	0.000984	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—NOS3—atherosclerosis	0.000193	0.00094	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CXCL8—atherosclerosis	0.000171	0.000834	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—AKT1—atherosclerosis	0.000165	0.000805	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—IL6—atherosclerosis	0.000163	0.000793	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—MMP9—atherosclerosis	0.000155	0.000754	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—NFKB1—atherosclerosis	0.000153	0.000746	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—MAPK8—atherosclerosis	0.00015	0.000733	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—AKT1—atherosclerosis	0.00015	0.000731	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—VEGFA—atherosclerosis	0.000139	0.000677	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—STAT3—atherosclerosis	0.000138	0.00067	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—MAPK3—atherosclerosis	0.000131	0.000641	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—TGFB1—atherosclerosis	0.000127	0.000621	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—IL6—atherosclerosis	9.61e-05	0.000468	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—AKT1—atherosclerosis	8.86e-05	0.000432	CbGpPWpGaD
